Introduction


According to the ADA (American diabetes association) 2014 guidelines, diabetes is diagnosed by one of the following: HbA 1c (hemoglobin A 1c ) of 6.5% or greater, fasting plasma glucose of 126 mg/dL or greater, two hour post oral glucose tolerance test plasma glucose of 200 mg/dL or greater, or in a patient with a random glucose of 200mg/dL or greater presenting with symptoms of hyperglycemia or hyperglycemic crisis. The goal HbA 1c in diabetic patients is less than 7% per ADA guidelines [1] . Initiation of an oral diabetic medication will provide a decrease in HbA 1c of 1-1.25% over the first 3-6 months [2] .
Uncontrolled diabetes can lead to long-term complications of the microvascular and macrovascular system. Microvascular complications include diabetic nephropathy, neuropathy and retinopathy. Diabetic nephropathy is the leading cause of chronic kidney disease in patients starting dialysis [3] . Diabetic retinopathy is one of the most common microvascular complications associated with diabetes [4] . Macrovascular complications include coronary artery disease, peripheral artery disease and stroke. It has been shown that reducing HbA 1c by 0.8% can reduce the risk of cardiovascular death by 45% [5] . It is evident that glycemic control in diabetics is very important for each patient. Several studies have demonstrated the benefit of glycemic control through pharmacist intervention [6] [7] [8] [9] [10] . This study originated as a way to justify pharmacist involvement with diabetes management. Due to the broad nature of the disease state, it was collectively decided to narrow the focus to insulin and other injectable agents and not include adjusting oral diabetic medications. The idea was to collect information to hopefully demonstrate positive results that could be used for future promotion of Clinic services.
The primary outcome was to evaluate glycemic control in patients requiring insulin therapy through close monitoring and routine follow up with pharmacists. This was measured by assessing the average change in HbA 1c following pharmacist intervention. The secondary outcomes were to measure the change in: weight over first follow-up period,
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HbA 1c over the second follow-up period, HbA 1c prior to initial Clinic visit, and HbA 1c with physician management compared to pharmacist management.
Methods
Clinic Description
LMHS (licking memorial health systems) is a not-for-profit healthcare organization dedicated to the mission of improving the health of the community. The Health Systems includes a 227-bed inpatient facility in addition to a professional corporation including a group of 100-plus physicians in various practices throughout Licking County. Over 5,000 patients within LMHS have been diagnosed with diabetes, which is nearly 15% of the patients of the LMHS patient population.
An LMHS primary care physician requested that diabetes management be incorporated into the established MTC (medication therapy clinic) where pharmacists provide medication management for anticoagulation therapy and patients with anemia and heart failure. Diabetes management was initially designed to help reduce hospital re-admissions, improve communication during transitions of care and provide more frequent monitoring of glucose readings by pharmacists. An endocrinologist accepted the role of medical director and created clearly defined guidelines and algorithms for dosing insulin, GLP-1 (glucagon-like peptide-1) agonist, and amylin mimetics utilizing ADA guidelines [1] . These guidelines ( Fig. 1 ) and all Clinic policies and procedures were approved by the P&T (pharmacy and therapeutics) and medical executive committees [1] . Clinic pharmacists underwent specialized training and obtained diabetes management certification. Signed physician referral forms received via EMR (electronic medical record) or fax included orders for pharmacist management based on these established guidelines. The referral forms included authorization to evaluate the need for CGM (continuous glucose monitors), basic laboratory standing orders, and referrals for DSMT (diabetes self-management training) or MNT (medical nutrition therapy). Referrals to the Clinic were limited to patients on insulin therapy, GLP-1 agonist or amylin mimetics. The goal was to achieve HbA 1c reductions through closer monitoring allowing more frequent opportunities for dose adjustments following approved guidelines and algorithms. In order to evaluate the effectiveness of this model, HbA 1c results were tracked during the course of treatment. In between Clinic visits, patients were asked to submit 
Intervention
Patient Selection
This retrospective chart review was completed for a total of 49 patients who were referred for an initial Clinic visit at the LMHS MTC by their endocrinologist (n = 36) or primary care physician (n = 13) during the designated time periods of the study: July 2012 to •Titration: Increase dose by 1-2 units or 10-15% one to two times weekly until SMBG target reached.
•For Hypoglycemia: Determine and address cause; decrease corresponding insulin dose by 2-4 units or 10-20%.
Option 2: Change to premixed insulin twice daily.
•Start: Divide current basal dose into 2/3 AM, 1/3 PM or 1/2 AM, 1/2 PM.
•Titration: Increase dose by 1-2 units or 10-15% one to two times weekly until individualized target achieved.
Insulin Dosing
Step 3: If A1c not at goal: Add 2 or more rapid-acting insulin injections before meals (basal-bolus dosing).
• Start: 4 units, 0.1 units/kg, or 10% basal dose/meal. If A1c < 8% consider decreasing the basal by same amount.
• Titration: Increase dose by 1-2 units or 10-15% once-twice weekly until SMBG target reached.
• For Hypoglycemia: Determine and address cause; decrease corresponding insulin dose by 2-4 units or 10-20%.
Bolus Insulin Dosing Correction Factor:
•Add 1 unit for every 50 mg/dL blood sugar is above 150 mg/dL.
•Decrease by 2 units for blood sugar less than 80 mg/dL.
Other Injectable Diabetes Medication:
•GLP-1 agonist and amylin mimetic -Titrate based on manufacturer recommendations.
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education while working closely with an endocrinologist in the office. The gap in-between study periods was used to set up services within the Clinic setting. This time period also included Clinic relocation and staffing changes which were not conducive to initiating additional Clinic services. During the first time period of the study, pharmacists managed patients in the endocrinology office to pilot the program. Once the Clinic relocation was complete and the billing process was set up, the pharmacists began managing patients within the Clinic during the second time period. Follow-up data collection after conclusion of the study was extended through April 2015. Approval for chart review was obtained from the P&T (Pharmacy and Therapeutics) committee. This study was not submitted for Institutional Review Board approval. A pharmacy student provided comprehensive chart review and collection of all data for the study. 
Statistical Analysis
Statistical analyses were conducted using the paired t-test for the primary outcome and the secondary outcomes of mean change in weight at the first follow-up and HbA 1c at second follow-up. A non-paired t-test was used to evaluate the secondary outcome that assessed the change in HbA 1c of insulin management by the Clinic pharmacists compared to physician managed prior to Clinic. Statistical significance was concluded with a p-value less than 0.05.
Results
A total of 49 patients were referred to the Insulin Clinic during the designated time period of the study. Of the 49 patients referred, 35 met the inclusion criteria for the primary outcome as shown in Fig. 2 . The baseline demographics of the 35 patients are provided in Table 1 and their diabetic treatment regimens are shown in Table 2 .
The primary outcome was the change in HbA 1c from baseline at initial Clinic visit to the first follow-up visit. The baseline HbA 1c average for the 35 Clinic patients was 9.5%. The average time period between initial Clinic visit and first follow-up HbA 1c was 83 (28 to 140) days. During the first follow-up period, the change in HbA 1c ranged from a 5.7% decrease to a 1.8% increase. The average HbA 1c at first follow-up was 8.7%, resulting in an average reduction of 0.8% (p = 0.015). Of the 35 patients, 24 of them had a decrease in HbA 1c.
The 35 Clinic patients included in the primary outcome of the study had an average increase in weight of two pounds (p = 0.279) over the 83 day average during the first follow-up period.
After assessment of first follow-up, a second follow-up HbA 1c was evaluated. Only 17 of the 35 patients had a HbA 1c that was 12-20 weeks after the previous HbA 1c from the first follow-up. Amongst the 17 patients included in the second follow-up, nine patients had a decrease in HbA 1c . Overall, the average change in HbA 1c was 0% (p = 0.967). The results ranged from a 2.5% decrease to a 2.2% increase for the second follow-up in HbA 1c .
To assess the change in HbA 1c prior to initial Clinic visit a HbA 1c within 20 weeks prior to initial Clinic visit was used. Of the 35 patients included in the study, Secondary outcomes also were evaluated and the results were not statistically significant. A small increase in weight was identified in the first follow-up period. Weight gain is a common adverse effect of insulin therapy which was an anticipated outcome. Results from a second follow-up were obtained to determine if a further reduction in HbA 1c were achieved and no change in HbA 1c was noted after an additional 12-20 week time period. The lack of difference between results demonstrates stability with extended pharmacist management beyond the first follow-up period. Unfortunately, less than half of the patients had results reported within the designated time period. Also, HbA 1c readings within 20 weeks prior to the initial baseline HbA 1c were evaluated. It was confirmed that patients were stable and mostly unchanged prior to initial Clinic referral as a slight increase was noted during this time of physician management. The HbA 1c changes between physician and pharmacist time periods were compared and the pharmacist's reduction further demonstrated the clinical importance of the results obtained in this study.
Numerous studies have shown the benefit of having pharmacists as a part of the healthcare team in relation to treating patients with diabetes. In these studies, pharmacists were able to help manage diabetes regardless of the patient's medication profile. Pharmacists were able to serve a more active role in the management of diabetic medications through initiating and adjusting both oral and injectable medications in these studies. [6] [7] [8] [9] [10] This study demonstrates the impact that pharmacists can have through management of only injectable diabetic medications. HbA 1c reductions were obtained through close monitoring and follow-up of glucose readings, conservative dosing guidelines and protocols, and direct pharmacist to patient interactions. Limitations were identified in this study. First off, patients were encouraged to document glucose readings, insulin dosing, as well as basic dietary information and report these details to the Clinic. This was done in a variety of ways and often was inconsistent in limiting the ability to make appropriate therapy modifications. With future studies, a more consistent approach utilizing electronic technology to download current glucometer results would be beneficial. Also, having complete autonomy with HbA 1c orders would narrow the timeframe between tests, allowing for more comparable results. Using a point-of-care device in conjunction with appointments would efficiently allow for quicker results and could contribute to improved visit compliance. Weights were recorded using different scales as some results were obtained by a combination of chart review and Clinic visits. This made it difficult to have a true measurement of weight change. Reviewing hypoglycemic events was limited to one health system. However, LMHS includes the only hospital and ED in the remote area as well as two urgent care facilities. It is reasonable that patients could have elected to have care provided outside of LMHS as two patients lived outside of the county.
Conclusion
Diabetes is a prevalent disease state that can lead to many devastating complications in patients with uncontrolled diabetes. Glycemic control can decrease the rates of cardiovascular disease and macrovascular and microvascular complications. Therefore, the importance of managing and controlling diabetes cannot be understated. Pharmacists play a vital role in improving the management of insulin and should be utilized routinely in patient-centered diabetes care.
